JP2017514895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514895A5 JP2017514895A5 JP2017508718A JP2017508718A JP2017514895A5 JP 2017514895 A5 JP2017514895 A5 JP 2017514895A5 JP 2017508718 A JP2017508718 A JP 2017508718A JP 2017508718 A JP2017508718 A JP 2017508718A JP 2017514895 A5 JP2017514895 A5 JP 2017514895A5
- Authority
- JP
- Japan
- Prior art keywords
- antigenic
- administered
- pathogen
- site
- microbial pathogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000890 antigenic Effects 0.000 claims 15
- 230000001717 pathogenic Effects 0.000 claims 13
- 244000052769 pathogens Species 0.000 claims 13
- 230000000813 microbial Effects 0.000 claims 10
- 238000002360 preparation method Methods 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 210000001519 tissues Anatomy 0.000 claims 5
- 210000004072 Lung Anatomy 0.000 claims 4
- 229940045505 Klebsiella pneumoniae Drugs 0.000 claims 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 3
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 claims 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 3
- 201000009910 diseases by infectious agent Diseases 0.000 claims 3
- 210000000987 Immune System Anatomy 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- 229940031000 Streptococcus pneumoniae Drugs 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 2
- 230000000051 modifying Effects 0.000 claims 2
- 230000002685 pulmonary Effects 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 230000003612 virological Effects 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 210000000936 Intestines Anatomy 0.000 claims 1
- 206010029803 Nosocomial infection Diseases 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 210000004304 Subcutaneous Tissue Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 230000002238 attenuated Effects 0.000 claims 1
- 230000003203 everyday Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000001681 protective Effects 0.000 claims 1
Claims (12)
- Klebsiella pneumoniaeの死滅細胞全体又は弱毒化細胞を含む、微生物病原体による脊椎動物宿主の肺組織における感染の治療的又は予防的処置に使用するための抗原性製剤であって、
前記微生物病原体が、Streptococcus pneumoniae、Pseudomonas aeruginosa、又はウイルス性の肺病原体であり、
前記抗原性製剤が、前記宿主の免疫系を調節するための有効量で投与部位に投与され、かつ、少なくとも1時間の投薬間隔で付与される連続投薬で投与され、その結果、2又は3以上の用量が、2日〜1ヶ月の期間にわたって、少なくとも1週間の投薬期間にわたって投与される、前記抗原性製剤。 - 投与部位が、皮膚又は皮下組織である、請求項1に記載の抗原性製剤。
- 投与部位が、腸内、非腸内、又は気道である、請求項1に記載の抗原性製剤。
- 投与部位が、肺でない、請求項1に記載の抗原性製剤。
- 投薬期間が、少なくとも2週間である、請求項1〜4のいずれかに記載の抗原性製剤。
- 各用量が投与部位において限局性の炎症性免疫応答を引き起こすのに有効であるように投与される、請求項1〜5のいずれかに記載の抗原性製剤。
- 投与部位における可視限局性炎症が1〜48時間以内に起こるように投与され、
任意で毎日又は一日おきに皮下投与される、請求項6に記載の抗原性製剤。 - 微生物病原体による感染に対する防御免疫を付与するのに有効な投薬計画で投与される、請求項1〜7のいずれかに記載の抗原性製剤。
- 宿主が、ヒト患者であり、
任意で前記患者が、免疫抑制又は免疫不全状態にある、請求項1〜8のいずれかに記載の抗原性製剤。 - 患者が、高齢患者又は小児患者である、請求項9に記載の抗原性製剤。
- 患者が、院内感染のリスクがある、請求項9又は10に記載の抗原性製剤。
- 第2異種微生物病原体に特異的な抗原決定基を含む、第1微生物病原体による脊椎動物宿主の標的組織における感染の治療的又は予防的処置に使用するための抗原性製剤であって、
前記抗原性製剤が、前記宿主の免疫系を調節するための有効量で投与部位に投与され、かつ、少なくとも1時間の投薬間隔で付与される連続投薬で投与され、その結果、2又は3以上の用量が、2日〜1ヶ月の期間にわたって、少なくとも1週間の投薬期間にわたって投与され、
前記第1微生物病原体が、Streptococcus pneumoniae又はPseudomonas aeruginosaであり、前記第2異種微生物病原体が、Klebsiella pneumoniaeであり、かつ、前記標的組織が、肺であるか;或いは
前記第1微生物病原体が、Pseudomonas aeruginosaであり、前記第2異種微生物病原体が、Streptococcus aureusであり、かつ、前記標的組織が皮膚であるか;或いは
前記第1微生物病原体が、ウイルス性の肺病原体であり、前記第2異種微生物病原体が、Klebsiella pneumoniaeであり、前記標的組織が肺であり;
任意で前記宿主がヒト患者である、前記抗原性製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461988117P | 2014-05-02 | 2014-05-02 | |
US61/988,117 | 2014-05-02 | ||
PCT/CA2015/050377 WO2015164979A1 (en) | 2014-05-02 | 2015-05-01 | Anti-microbial immunomodulation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017514895A JP2017514895A (ja) | 2017-06-08 |
JP2017514895A5 true JP2017514895A5 (ja) | 2018-06-14 |
JP6632607B2 JP6632607B2 (ja) | 2020-01-22 |
Family
ID=54357960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017508718A Active JP6632607B2 (ja) | 2014-05-02 | 2015-05-01 | 抗微生物免疫修飾 |
Country Status (8)
Country | Link |
---|---|
US (4) | US10251946B2 (ja) |
EP (1) | EP3137108A4 (ja) |
JP (1) | JP6632607B2 (ja) |
CN (2) | CN106456740B (ja) |
AU (2) | AU2015252726B2 (ja) |
CA (1) | CA2947631A1 (ja) |
RU (2) | RU2020120075A (ja) |
WO (1) | WO2015164979A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106456740B (zh) * | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | 抗微生物免疫调节 |
CA3061077A1 (en) | 2016-04-26 | 2017-11-02 | Qu Biologics Inc. | Therapeutically triggering an innate immune response in a target tissue |
US20210353693A1 (en) * | 2018-10-17 | 2021-11-18 | SciBac Inc. | Live Biotherapeutics to Treat and Prevent Lung Conditions |
US20230364162A1 (en) * | 2020-09-28 | 2023-11-16 | The Regents Of The University Of Michigan | Methods and compositions for intestinal inflammation |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3928565A (en) | 1971-10-19 | 1975-12-23 | Yuzuru Homma | Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties |
JPS5946493B2 (ja) | 1978-03-31 | 1984-11-13 | 株式会社三和化学研究所 | 異種死菌体混合物を有効成分とする抗腫瘍剤 |
JPS568320A (en) | 1979-07-04 | 1981-01-28 | Chisato Maruyama | Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent |
JPS56108716A (en) | 1980-01-30 | 1981-08-28 | Sanwa Kagaku Kenkyusho:Kk | Antiviral agent containing different kind dead cell mixture as effective component |
JPS5839624A (ja) | 1981-09-02 | 1983-03-08 | Meiji Seika Kaisha Ltd | 抗腫瘍剤 |
JPS6012071A (ja) | 1983-06-30 | 1985-01-22 | 東レ株式会社 | 抗腫瘍作用を有する体液処理剤 |
US4880626A (en) | 1985-01-18 | 1989-11-14 | Mcmichael John | Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome |
US5292513A (en) | 1992-05-18 | 1994-03-08 | Anthony G. Gristina | Method for nonspecific cellular immune stimulation |
US5652332A (en) | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
GB9406301D0 (en) | 1994-03-30 | 1994-05-25 | Univ London | Immunotherapeutic agent and its use |
US6902743B1 (en) | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
US5869057A (en) | 1995-06-07 | 1999-02-09 | Rock; Edwin P. | Recombinant vaccines to break self-tolerance |
WO1997036614A1 (en) | 1996-03-29 | 1997-10-09 | Terman David S | Polymerized staphylococcal protein a for treatment of diseases |
US6348586B1 (en) | 1996-07-25 | 2002-02-19 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
US6028060A (en) | 1997-01-29 | 2000-02-22 | Vanderbilt University | Treatment of chronic inflammatory diseases with CM101/GBS toxin |
AU762481C (en) | 1998-03-27 | 2004-08-19 | Oregon Health Sciences University | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders |
WO2001056387A1 (en) | 2000-02-01 | 2001-08-09 | Donnell Michael A O | Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen |
US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
TWI306760B (en) | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
FR2816844A1 (fr) | 2000-11-17 | 2002-05-24 | Pf Medicament | Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur et/ou adjuvant |
GB2370770B (en) | 2001-01-03 | 2005-06-01 | Simon Connolly | Uses of Streptococcus Vaccines |
FR2822071B1 (fr) | 2001-03-15 | 2005-07-01 | Pf Medicament | Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques |
ES2622468T3 (es) | 2001-03-29 | 2017-07-06 | Synergy Pharmaceuticals, Inc. | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis |
WO2003009859A1 (fr) | 2001-07-19 | 2003-02-06 | Azuma, Ichiro | Immunotherapie pour humains |
EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
AU2002353366A1 (en) | 2001-12-10 | 2003-06-23 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
NZ555055A (en) | 2001-12-11 | 2010-06-25 | Pasteur Institut | Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
WO2003063593A1 (en) | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
JP2005531289A (ja) | 2002-02-15 | 2005-10-20 | アゲルプ ファーマ ゲーエムベーハー | S.aureusエンテロトキシンB由来の免疫調節ペプチド |
WO2003104272A1 (en) | 2002-06-11 | 2003-12-18 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions |
JP4618970B2 (ja) | 2002-08-02 | 2011-01-26 | マルホ株式会社 | 肛門圧低下外用剤 |
IL152127A0 (en) | 2002-10-06 | 2003-05-29 | Bio Balance Corp | Probiotic compositions for the treatment of inflammatory bowel disease |
WO2004064717A2 (en) | 2003-01-21 | 2004-08-05 | Yeda Research And Development Co. Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
PE20050068A1 (es) | 2003-02-06 | 2005-03-11 | Novartis Ag | 2-cianopirrolopirimidinas como inhibidores de la catepsina s |
US7939076B2 (en) | 2003-04-23 | 2011-05-10 | Medarex, Inc. | Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist |
US7413728B2 (en) | 2003-11-14 | 2008-08-19 | Ucl Biomedica Plc | Immune modulator |
US20050175630A1 (en) | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
US8034359B2 (en) * | 2004-06-07 | 2011-10-11 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to cancers |
US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
NZ581806A (en) * | 2004-06-07 | 2011-10-28 | Qu Biolog Inc | Bacterial compositions for the treatment of cancer |
US8501198B2 (en) * | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
US8029777B2 (en) | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
EP2040724B1 (en) | 2006-05-18 | 2011-10-05 | Biobalance Llc | Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof |
WO2008026999A2 (en) | 2006-08-28 | 2008-03-06 | Omnio Healer Ab | Candidates against infection |
NZ715882A (en) | 2006-10-27 | 2017-07-28 | Qu Biologics Inc | Tissue targeted antigenic activation of the immune response to treat cancers |
CA2571805C (en) | 2006-10-27 | 2018-05-01 | Harold David Gunn | Tissue targeted antigenic activation of the immune response to cancers |
BRPI0721892A2 (pt) | 2007-07-23 | 2014-05-13 | Vaccine Res Internat Plc | Composição de vacina, inalador, célula, métodos para vacinar um animal contra uma infecção bacteriana, para preparar uma linhagem de célula de hibridoma, e para preparar uma vacina para um patógeno bacteriano, usos de uma composição, de soros humanos, e de um anticorpo humano, linhagem de célula de hibridoma, anticorpo, fragmento de ligação ativo, soro, processo para a produção de uma vacina, e, cultura de célula bacteriana |
WO2009021977A1 (en) | 2007-08-16 | 2009-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human specific escherichia coli strains |
US20110027348A1 (en) | 2007-08-27 | 2011-02-03 | Janos Feher | Composition and method inhibiting inflammation |
WO2010068413A1 (en) | 2008-11-25 | 2010-06-17 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
US20100310656A1 (en) * | 2009-04-27 | 2010-12-09 | Immunitor USA, Inc. | Immunotherapy and prevention of autoimmune hepatitis |
EP3235506B1 (en) * | 2010-07-26 | 2023-12-06 | Qu Biologics Inc. | Immunogenic anti-inflammatory compositions |
US8980279B2 (en) * | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
WO2015073801A1 (en) * | 2013-11-14 | 2015-05-21 | Duke University | Tetanus toxoid and ccl3 improve dc vaccines |
CN106456740B (zh) * | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | 抗微生物免疫调节 |
-
2015
- 2015-05-01 CN CN201580030591.XA patent/CN106456740B/zh active Active
- 2015-05-01 CA CA2947631A patent/CA2947631A1/en active Pending
- 2015-05-01 RU RU2020120075A patent/RU2020120075A/ru unknown
- 2015-05-01 JP JP2017508718A patent/JP6632607B2/ja active Active
- 2015-05-01 WO PCT/CA2015/050377 patent/WO2015164979A1/en active Application Filing
- 2015-05-01 US US15/308,302 patent/US10251946B2/en active Active
- 2015-05-01 EP EP15786308.5A patent/EP3137108A4/en active Pending
- 2015-05-01 AU AU2015252726A patent/AU2015252726B2/en active Active
- 2015-05-01 RU RU2016147048A patent/RU2724895C2/ru active
- 2015-05-01 CN CN202110547299.2A patent/CN113855791A/zh active Pending
-
2019
- 2019-01-31 US US16/264,040 patent/US10946083B2/en active Active
-
2020
- 2020-12-01 AU AU2020281030A patent/AU2020281030A1/en active Pending
-
2021
- 2021-01-21 US US17/154,536 patent/US11819543B2/en active Active
-
2023
- 2023-10-12 US US18/379,422 patent/US20240091330A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017514895A5 (ja) | ||
HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
JP2016074740A5 (ja) | ||
JP2013155188A5 (ja) | ||
NO20073868L (no) | Levende attenuert rotavirus vaksine for oral administrering | |
JP2015057451A5 (ja) | ||
NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
JP2016539105A5 (ja) | ||
MX351380B (es) | Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino. | |
RU2016147048A (ru) | Противомикробная иммуномодуляция | |
HRP20210418T1 (hr) | Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1 | |
MX2015016750A (es) | Composicion inmunogenica para uso en terapia. | |
JP2015514093A5 (ja) | ||
BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
NZ703729A (en) | Combinations with a backbone-cyclized peptide | |
JP2015533131A5 (ja) | ||
CN106176989A (zh) | 一种治肺脓疡的配方 | |
Seyman et al. | Acute Brucellosis Following Accidental Exposure to Brucella melitensis Rev-1 Vaccine | |
Savvidou et al. | Primary pyomyositis and disseminated septic pulmonary emboli: a reactivated staphylococcal infection? | |
Chiricozzi | Secukinumab in the therapy of psoriasis and psoriatic arthritis: a safe choice in clinical practice | |
Woodward | Immunisation of older people | |
Yenigün et al. | Severe pain, spasticity, and heterotopic ossification in a patient with spinal cord injury: a vicious circle and management with baclofen pump | |
Malcolmson et al. | Safety and efficacy of biweekly Hizentra® administration in patients with primary immunodeficiency diseases: A retrospective single-center study | |
Melamed et al. | Long-term tolerability and safety of facilitated-subcutaneous infusion of human immune globulin G (IgG), 10%, and recombinant human hyaluronidase (rHuPH20)(IGHy): a Phase 3 extension study in patients with primary immunodeficiencies (PIs) | |
Boussouar et al. | Atypical presentation of CMV pneumonia in a heart transplant patient |